Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of Lorcaserin as Adjunctive Treatment in Subjects With Dravet Syndrome

NCT04572243 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.

NCT NCT04572243
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04572243 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of Lorcaserin as Adjunctive Treatment in Subjects With Dravet Syndrome
Lead sponsor
Eisai Inc.
Phase
Phase 3
Overall status
Terminated
Start date
September 23, 2020
Completion date
August 15, 2024
Enrollment
22 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

epilepsies, myoclonic